Physiologically‐based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co‐administered with ritonavir

• Päätekijät: Zexu Sun (Tekijä), Nan Zhao (Tekijä), Ran Xie (Tekijä), Bo Jia (Tekijä), Junyu Xu (Tekijä), Lin Luo (Tekijä), Yulei Zhuang (Tekijä), Yuyu Peng (Tekijä), Xinchang Liu (Tekijä), Yingjun Zhang (Tekijä), Xia Zhao (Tekijä), Zhaoqian Liu (Tekijä), Yimin Cui (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2024-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract GLS4 is a first‐in‐class hepatitis B virus (HBV) capsid assembly modulator (class I) that is co‐administered with ritonavir to maintain the anticipated concentration required for the effective antiviral activity of GLS4. In this study, the first physiologically‐based pharmacokinetic (PBPK)...